Intra-Cellular Therapies Inc. (NASDAQ:ITCI) fell 2.8% on Wednesday . The company traded as low as $39.56 and last traded at $39.89, with a volume of 185,940 shares changing hands. The stock had previously closed at $41.04.

A number of brokerages recently weighed in on ITCI. Leerink Swann reaffirmed a “buy” rating and set a $95.00 price objective on shares of Intra-Cellular Therapies in a research report on Thursday, August 11th. Cowen and Company reaffirmed a “buy” rating and set a $75.00 price objective on shares of Intra-Cellular Therapies in a research report on Friday, August 5th. Piper Jaffray Cos. began coverage on shares of Intra-Cellular Therapies in a research report on Wednesday, June 1st. They set an “overweight” rating and a $57.00 price objective for the company. Finally, Zacks Investment Research downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Wednesday, July 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $70.78.

The stock’s 50-day moving average is $40.53 and its 200-day moving average is $34.78. The company’s market capitalization is $1.74 billion.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.79) by $0.08. The company had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.02 million. The firm’s quarterly revenue was up 283.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.61) EPS. On average, equities analysts anticipate that Intra-Cellular Therapies Inc. will post ($3.17) EPS for the current fiscal year.

Other hedge funds and institutional investors recently bought and sold shares of the company. Rhumbline Advisers raised its position in Intra-Cellular Therapies by 33.1% in the fourth quarter. Rhumbline Advisers now owns 25,503 shares of the biopharmaceutical company’s stock worth $1,372,000 after buying an additional 6,345 shares during the last quarter. New York State Common Retirement Fund raised its position in Intra-Cellular Therapies by 27.9% in the fourth quarter. New York State Common Retirement Fund now owns 26,600 shares of the biopharmaceutical company’s stock worth $1,431,000 after buying an additional 5,800 shares during the last quarter. BlackRock Advisors LLC raised its position in Intra-Cellular Therapies by 1.7% in the fourth quarter. BlackRock Advisors LLC now owns 1,199,043 shares of the biopharmaceutical company’s stock worth $64,497,000 after buying an additional 19,938 shares during the last quarter. California Public Employees Retirement System raised its position in Intra-Cellular Therapies by 505.4% in the fourth quarter. California Public Employees Retirement System now owns 78,700 shares of the biopharmaceutical company’s stock worth $4,233,000 after buying an additional 65,700 shares during the last quarter. Finally, Jennison Associates LLC raised its position in Intra-Cellular Therapies by 212.9% in the fourth quarter. Jennison Associates LLC now owns 1,257,846 shares of the biopharmaceutical company’s stock worth $67,660,000 after buying an additional 855,846 shares during the last quarter.

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.